EndoCyclic Therapeutics

EndoCyclic Therapeutics is pioneering a novel class of precision peptide therapeutics and diagnostics based on a platform technology that enables selective uptake and pH-sensitive activation within diseased cells. The company's pipeline is focused on high-need areas, including endometriosis, where it is advancing both a potential disease-modifying therapeutic (ENDO-205) and a non-invasive diagnostic (FemLUNA), as well as oncology programs. With an IND cleared for its lead candidate, EndoCyclic is positioned to address significant unmet medical needs with a targeted, non-hormonal approach that aims to avoid systemic toxicity.

Proprietary platform of cell-permeating, pH-sensitive peptides designed for selective uptake and activation within diseased tissue, enabling targeted therapeutics and diagnostics.

In endometriosis, EndoCyclic faces competition from companies developing new hormonal therapies, GnRH antagonists, and non-hormonal approaches (e.g., neurokinin inhibitors), but its potential 'curative' claim and diagnostic pairing are differentiating. In oncology, it competes in a crowded field of targeted therapies and must prove its intracellular targeting offers advantages over existing modalities.